SecBot SecBot
PRESS-RELEASE ·Filed Jun 5, 2026

NRXP

NRx Pharmaceuticals, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The real-world evidence significantly strengthens NRx's NDA filing for NRX-100, especially with regulatory tailwinds from the White House and Congress. Monitor for FDA acceptance of the NDA and any Type C meeting outcomes.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$4.14
T+0 close · Jun 5, 2026 · via day close
Latest settled
−15.94%
T+60 · $3.48
Vs SPY
−19.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $4.14entry
  2. T+1 · 5mo ago +4.59%α +4.36% · $4.33
  3. T+5 · 5mo ago −7.25%α −7.82% · $3.84
  4. T+20 · 4mo ago −4.71%α −6.57% · $3.95
  5. T+60 · 3mo ago −15.94%α −19.94% · $3.48
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

NRx Pharmaceuticals announced the presentation of a peer-reviewed poster at the 2026 ASCP conference showing that IV ketamine (NRX-100) demonstrated significantly higher remission and response rates vs. intranasal esketamine in a real-world study of over 10,000 patients. The data supports NRx's NDA filing for NRX-100 in suicidal depression, with the FDA emphasizing real-world evidence via a recent Executive Order and Congressional language.

Key Facts

  • IV ketamine patients showed 50% higher odds of remission (OR 1.51; P<.001) and 22% higher odds of response (OR 1.22; P<.003) vs. intranasal esketamine.
  • Study analyzed 8,224 IV ketamine and 1,830 intranasal esketamine patients from 800 community clinics.
  • 34% of IV ketamine patients achieved remission vs. 26% for esketamine; 63% vs. 58% response rate.
  • NRx has filed an NDA for NRX-100 (IV ketamine) with a National Priority Voucher Program application for suicidal depression.
  • White House Executive Order and House Appropriations language support use of real-world evidence for depression drug approvals.
  • NRx has Fast Track Designation for NRX-100 in suicidal depression and Breakthrough Therapy Designation for NRX-101 in suicidal bipolar depression.

Financial Impact

No financial figures disclosed; potential market opportunity for NRX-100 in suicidal depression (large unmet need) but no revenue or deal value provided.

Risk Factors

  • Study limitations: non-randomized design, potential unmeasured confounding variables.
  • FDA may still require randomized controlled trials for full approval, despite real-world evidence support.
  • NRx is a clinical-stage biopharma with no approved products and no disclosed revenue.
  • Competition from existing esketamine (Spravato) and other NMDA-targeting therapies.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3307371

Track record

22 reports on NRXP

Performance horizon

8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.

Filters
  1. Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  2. Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
  3. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
  4. Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
  5. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
  6. Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
  7. Sep 15, 20268w ago 8-K Bullish 5/10 Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
  8. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
  9. Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
  10. Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
Showing 10 of 22

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026